Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving luciferase
Reexamination Certificate
2005-05-14
2011-10-25
Kam, Chih-Min (Department: 1656)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving luciferase
C435S288700, C435S288200, C436S063000
Reexamination Certificate
active
08043826
ABSTRACT:
The invention provides a method of monitoring the response of platelets to a COX1 inhibitor such as aspirin. The method involves collecting platelet-containing mammalian blood treated with a COX 1 inhibitor; mixing the blood with a COX 1-dependent platelet agonist, such as arachidonic acid, monitoring extracellular ATP in the agonist-activated blood to generate a measurement, and comparing the measurement to a standard value. Devices, systems, and kits for carrying out the method are also provided.
REFERENCES:
patent: 6716391 (2004-04-01), Olson
patent: 05772254 (2008-10-01), None
patent: WO 0117649 (2001-03-01), None
patent: WO2005113800 (2005-12-01), None
Scazziota et al. ,Thrombosis Research 100 479-488 (2000).
Abraham, E.H., et al., “Erythrocyte membrane ATP' binding cassette (ABC) proteins: MRP1 and CFTR as well as CD39 (ectopyrase) involved in RBC AT”, “Blood Cells Molecules and Diseases”, 2001, pp. 165-180, vol. 27.
Accumetrics (Company), “VerifyNow Asprin Assay”, “web address: http://www.accumetrics.com/products/ultegra—asa.html.”, 1996, Publisher: Accumetrics.
Altman, R., et al., “The antithrombotic profile of aspirin. Aspirin resistance, or simply failure?”, “Thrombosis J.”, 2004, pp. 1-8, vol. 2.
Bhatt, D.L., et al., “Aspirin resistance: more than just a laboratory curiosity”, “J. Am. College of Cardiology”, 2004, vol. 43, No. 6.
Biocarta (Company), “Pathways: Asprin Blocks Signaling Pathway Involved in Platelet Application”, “Charting Pathways of Life http://www.biocarta.com/pathfiles/h—sppaPathway.asp.”, 2004.
Bolla, M., et al., “Cyclooxygenase involvement in thromboxane-dependent . . . ”, “Hypertension”, 2004, pp. 1264-1269 , vol. 43.
Born, G.V.R., “Aggregation of Blood Platelets by Adenosine Diphosphate and Its Reversal”, “Nature”, Jun. 9, 1962, pp. 927-929, vol. 194, No. 4832.
Chen, W.H., et al., “Aspirin resistance is associated with a high incidence of myonecrosis . . . ”, “J. Am. Coll. Cardiol.”, 2004, pp. 1127-1129, vol. 43.
Cho, et al., “The roles of LAT in platelet signaling induced by collagen, TxA2, or ADP”, “Biochem Biophys Res Comm”, 2002, pp. 916-921, vol. 292.
De Gaetano, G., et al., “Aspirin resistance: a revival of platelet aggregation tests?”, “J. Thrombosis and Haemostasis”, 2003, pp. 2048-201, vol. 1.
Gum, P.A., et al., “Profile and prevalance of aspirin resistance in patients with cardiovascular disease”, “Am. J. Cardiology”, 2001, p. 230, vol. 88.
Knoffler, et al., “Critical evaluation of the quantification of ATP release reaction in whole blood”, “Thrombosis Res”, 1996, pp. 157-165, vol. 84, No. 3.
Miller, Jonathan L., “Platelet Function Testing: An Improved Approach Utilizing Lumi-aggregation and an Interactive Computer System”, “Division of Clinical Pathology, State University of New York, Upstate Medical Center, Syracuse, New York”, Apr. 1984, pp. 471-476, vol. 81, No. 4.
Puri, “Phospholipase A2: its role in ADP- and thrombin-induced platelet activation mechanisms”, “Int J Biochem Cell Biol”, 1998, pp. 1107-1122, vol. 30.
Rodgers, G.M., “Overview of platelet physiology and laboratory evaluation of platelet function”, “Clin. Obstet. Gynecol”, 1999, pp. 349-359, vol. 42.
Scazziota, et al., “Abciximab treatment in vitro after aspirin treatment in vivo has additive effects on platelet aggregation, ATP release,”, “Thrombosis Res”, 2000, pp. 479-488, vol. 100.
Steinhubl, et al., “Point-of-care measured platelet inhibition correlates . . . ”, “Circulation”, , pp. 2572-2578, vol. 103, (2001).
Stiene-Martin, et al., “The Megakaryocyte-Platelet System”, “Clinical Hematology: Principles, Procedures, Correlations”, 1998, vol. 2.
Taylor, et al., “The differential effect of aspirin on human platelet activation in aspirin-sensitive asthmatics and normal subjects”, “British J. Clin. Pharmacology”, 1993, pp. 227-234, vol. 35.
Vane, J.R., et al., “The mechanism of action of aspirin.”, “Thrombosis Research”, 2003, pp. 255-258, vol. 110.
Wu, K.K. et al., “Monitoring platelet function in glycoprotein IIb/IIIa inhibitor therapy”, “Circulation”, , pp. 2528-2530, vol. 103, (2001).
Kam Chih-Min
King David J.
Lemaire Charles A.
Lemaire Patent Law Firm, P.L.L.C.
Medical Innovations International, Inc.
LandOfFree
Device for monitoring inhibition of platelet function response does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Device for monitoring inhibition of platelet function response, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Device for monitoring inhibition of platelet function response will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4278278